Supplements
High-flow nasal cannula reduces treatment failure risk compared to conventional oxygen therapy in pediatric acute respiratory failure
In children with acute respiratory failure, high-flow nasal cannula (HFNC) significantly lowers the risk of treatment failure compared to conventional oxygen therapy (OR: 0.509, 95% CI: 0.42-0.61). However, HFNC does not significantly differ from CPAP in intubation rates or hospital mortality, and may be associated with a non-significant increase in treatment failure versus CPAP.
Evidence Score
Evidence Score49/100
Human RCT
Meta-analysis
Mechanism
Safety
Confidencelow
Mechanism Graph
HFNC delivers heated, humidified oxygen at high flow rates
↓
Reduces anatomical dead space and provides positive end-expiratory pressure
↓
Improves oxygenation and work of breathing
↓
Result: Lower risk of treatment failure compared to conventional oxygen therapy
Limitations
- ⚠Comparison with CPAP did not reach statistical significance, limiting conclusions about superiority
- ⚠Heterogeneity in definitions of treatment failure and underlying conditions across included RCTs
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.